Robert Stratford

Dr. Robert Stratford


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
CSChandler Schexnayder
Chandler Schexnayder
RSRobert Stratford
Robert Stratford
The goal of the present study was to determine the effects of glyceollins on intestinal ABCC2 (ATP Binding Cassette C2, multidrug resistance protein 2, MRP2) and ABCG2 (ATP Binding Cassette G2, breast cancer resistance protein, BCRP) function using the Caco-2 cell intestinal epithelial cell model. Glyceollins are soy-derived phytoestrogens that demonstrate anti-proliferative activity in several sources of cancer cells. 5 (and 6)-carboxy-2′,7′-dichloroflourescein (CDF) was used as a prototypical MRP2 substrate; whereas BODIPY-prazosin provided an indication of BCRP function. Comparison studies were conducted with genistein. Glyceollins were shown to inhibit MRP2-mediated CDF transport, with activity similar to the MRP2 inhibitor, MK-571. They also demonstrated concentration-dependent inhibition BCRP-mediated efflux of BODIPY-prazosin, with a potency similar to that of the recognized BCRP inhibitor, Ko143. In contrast, genistein did not appear to alter MRP2 activity and even provided a modest increase in BCRP efflux of BODIPY-prazosin. In particular, glyceollin inhibition of these two important intestinal efflux transporters suggests the potential for glyceollin to alter the absorption of other phytochemicals with which it might be co-administered as a dietary supplement, as well as alteration of the absorption of pharmaceuticals that may be administered concomitantly.

1 May 2016 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
TCThomas I.F.H. Cremers
Thomas I.F.H. Cremers
GFGunnar Flik
Gunnar Flik
JFJoost H.A. Folgering
Joost H.A. Folgering
HRHans Rollema
Hans Rollema
RSRobert Stratford
Robert Stratford
Administration of bupropion and its preformed active metabolite, hydroxybupropion, to rats with measurement of unbound concentrations by quantitative microdialysis sampling of plasma and brain extracellular fluid, was used to develop a compartmental PK model to describe the blood-brain barrier transport of both substances. The population model revealed rapid equilibration of both entities across the blood-brain barrier with resultant Kp,uu,ss estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, thus indicative of a net uptake asymmetry. An overshoot of the brain extracellular fluid concentration to plasma unbound concentration ratio at early time points was observed with bupropion; this was modeled as a time dependent uptake clearance of the drug across the blood-brain barrier. Translation of the model was used to predict bupropion and hydroxybupropion exposure in human brain extracellular fluid following twice daily administration of 150 mg bupropion. Predicted concentrations indicate that preferential inhibition of the dopamine and norepinephrine transporters by the metabolite, with little to no contribution by bupropion, would be expected at this therapeutic dose. These results, therefore, extend nuclear imaging studies on dopamine transporter occupancy, and suggest that inhibition of both transporters contributes significantly to bupropion's therapeutic efficacy.

1 February 2016 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
CCChukwuemezie Chimezie
Chukwuemezie Chimezie
AEAdina Ewing
Adina Ewing
CSChandler Schexnayder
Chandler Schexnayder
MBMelyssa Bratton
Melyssa Bratton
EGElena Glotser
Elena Glotser
RSRobert Stratford
Robert Stratford